WallStreetZenWallStreetZen

NASDAQ: GRI
Gri Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for GRI

Based on 2 analysts offering 12 month price targets for Gri Bio Inc

Min Forecast
$10.00+536.94%
Avg Forecast
$18.50+1,078.34%
Max Forecast
$27.00+1,619.75%

Should I buy or sell GRI stock?

Based on 2 analysts offering ratings for Gri Bio Inc.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GRI stock forecasts and price targets.

GRI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-10
lockedlocked$00.00+00.00%2026-08-21

1 of 1

Forecast return on equity

Is GRI forecast to generate an efficient return?

Company
-3.65%
Industry
-16.81%
Market
154.98%
GRI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GRI forecast to generate an efficient return on assets?

Company
-3.3%
Industry
-3.72%
GRI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GRI earnings per share forecast

What is GRI's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$3.78
Avg 2 year Forecast
-$2.02
Avg 3 year Forecast
-$0.17

GRI revenue forecast

What is GRI's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

GRI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GRI$1.57$18.50+1,078.34%Buy
ERNA$2.11N/AN/A
NRSN$2.13$52.00+2,341.31%Buy
DRMA$0.84N/AN/A
CVKD$0.94N/AN/A
View Top Biotech Stocks

Gri Bio Stock Forecast FAQ

Is Gri Bio Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: GRI) stock is to Buy GRI stock.

Out of 2 analysts, 0 (0%) are recommending GRI as a Strong Buy, 2 (100%) are recommending GRI as a Buy, 0 (0%) are recommending GRI as a Hold, 0 (0%) are recommending GRI as a Sell, and 0 (0%) are recommending GRI as a Strong Sell.

If you're new to stock investing, here's how to buy Gri Bio stock.

What is GRI's earnings growth forecast for 2026-2028?

(NASDAQ: GRI) Gri Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 66.02%.

Gri Bio's earnings in 2026 is -$9,659,000.On average, 3 Wall Street analysts forecast GRI's earnings for 2026 to be -$8,268,980, with the lowest GRI earnings forecast at -$8,848,082, and the highest GRI earnings forecast at -$7,712,614. On average, 3 Wall Street analysts forecast GRI's earnings for 2027 to be -$4,415,952, with the lowest GRI earnings forecast at -$8,119,668, and the highest GRI earnings forecast at -$482,038.

In 2028, GRI is forecast to generate -$375,356 in earnings, with the lowest earnings forecast at -$364,207 and the highest earnings forecast at -$390,222.

What is GRI's revenue growth forecast for 2026-2028?

(NASDAQ: GRI) Gri Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 44.09%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.88%.

Gri Bio's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast GRI's revenue for 2026 to be $0, with the lowest GRI revenue forecast at $0, and the highest GRI revenue forecast at $0. On average, 3 Wall Street analysts forecast GRI's revenue for 2027 to be $0, with the lowest GRI revenue forecast at $0, and the highest GRI revenue forecast at $0.

In 2028, GRI is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is GRI's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: GRI) forecast ROA is -3.3%, which is higher than the forecast US Biotechnology industry average of -3.72%.

What is GRI's Price Target?

According to 2 Wall Street analysts that have issued a 1 year GRI price target, the average GRI price target is $18.50, with the highest GRI stock price forecast at $27.00 and the lowest GRI stock price forecast at $10.00.

On average, Wall Street analysts predict that Gri Bio's share price could reach $18.50 by Sep 10, 2027. The average Gri Bio stock price prediction forecasts a potential upside of 1,078.34% from the current GRI share price of $1.57.

What is GRI's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: GRI) Gri Bio's current Earnings Per Share (EPS) is -$15.12. On average, analysts forecast that GRI's EPS will be -$3.78 for 2026, with the lowest EPS forecast at -$4.05, and the highest EPS forecast at -$3.53. On average, analysts forecast that GRI's EPS will be -$2.02 for 2027, with the lowest EPS forecast at -$3.71, and the highest EPS forecast at -$0.22. In 2028, GRI's EPS is forecast to hit -$0.17 (min: -$0.17, max: -$0.18).

What is GRI's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: GRI) forecast ROE is -3.65%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.